Denise Sterling served as Executive Vice President and Chief Financial Officer of Core Scientific, Inc. until her resignation effective March 17, 2025, coinciding with the appointment of successor CFO James P. Nygaard, Jr.
Under a transition agreement dated November 2024, Sterling received a $500,000 retention bonus contingent on employment through December 31, 2024 and a one-time RSU award of 318,613 units vesting March 31, 2025. She continued as an employee through January 16, 2026, performing transition services and receiving senior management-level compensation. Upon final separation, her unvested equity awards were fully accelerated. During 2025, she realized $5.8 million from vesting of 557,614 RSUs.
Biography extracted from Core Scientific DEF 14A filed 2026-03-31 View cached copy (2026-08-31)Live source ↗
Roles
Contiguous filings for the same role are collapsed into a single tenure span. Click a row to see the underlying filings.
| Company | Role | Tenure | Filings |
|---|---|---|---|
| Core Scientific | Chief Financial Officer | 2022-04 → present (4y 7mo) | 9 |
Show 9 underlying filings | |||
Insider transactions
Totals for this person
| Bucket | Invested (shares) | Invested (USD) | Divested (shares) | Divested (USD) | Net direction | Txns | Invested @ last price | Divested @ last price |
|---|---|---|---|---|---|---|---|---|
| All time | 3,775,760 | $0 | 3,108,956 | $248.3K | ↓ Divested $248.3K | 14 | $50.03M | $41.19M |
| 2025 | - | $0 | 802 | $12.5K | ↓ Divested $12.5K | 1 | $0 | $10.6K |
| 2024 | 2,215,708 | $0 | 3,066,574 | $151.7K | ↓ Divested $151.7K | 10 | $29.36M | $40.63M |
| 2022 | 1,560,052 | $0 | 41,580 | $84.0K | ↓ Divested $84.0K | 3 | $20.67M | $550.9K |
| 2024-Q1 | 1,897,095 | $0 | 3,053,561 | $53.8K | ↓ Divested $53.8K | 7 | $25.14M | $40.46M |
| 2024-Q2 | - | $0 | 4,261 | $15.6K | ↓ Divested $15.6K | 1 | $0 | $56.5K |
| 2024-Q3 | 318,613 | $0 | 8,752 | $82.4K | ↓ Divested $82.4K | 2 | $4.22M | $116.0K |
| 2025-Q1 | - | $0 | 802 | $12.5K | ↓ Divested $12.5K | 1 | $0 | $10.6K |
Invested = shares acquired (buys, grants, option exercises) — insider adding to the position. Divested = shares reduced (sells, dispositions, tax-withholding) — cash flowing TO the insider. Net direction shows which side wins on dollar terms in each bucket. % of holder's stake not yet computed (pending Form 3/4 holdings ingest). See methodology. The two @ last price columns restate the same share counts at the most recent share price we read (close of 2026-10-30); they are a valuation, not a cash flow, and they move every day the market does.
All transactions
| Date | Company | Kind | Shares | Amount (USD) | Value @ last price |
|---|---|---|---|---|---|
| 2025-01-22 | Core Scientific | Open-market sale | 802 | $12,544 | $10.6K |
| 2024-09-05 | Core Scientific | Grant / award / vesting | 318,613 | - | $4.22M |
| 2024-08-16 | Core Scientific | Open-market sale | 8,752 | $82,374 | $116.0K |
| 2024-05-13 | Core Scientific | Open-market sale | 4,261 | $15,595 | $56.5K |
| 2024-02-22 | Core Scientific | Tax withholding on vesting | 16,617 | $53,756 | $220.2K |
| 2024-01-23 | Core Scientific | Sale to issuer (buyback) · Common Stock, par value $0.0001 per share | 1,518,472 | - | $20.12M |
| 2024-01-23 | Core Scientific | Grant / award / vesting · Common Stock, par value $0.00001 per share | 151,847 | - | $2.01M |
| 2024-01-23 | Core Scientific | Grant / award / vesting · Tranche 1 Warrants | 123,696 | - | $1.64M |
| 2024-01-23 | Core Scientific | Grant / award / vesting · Tranche 2 Warrants | 103,080 | - | $1.37M |
| 2024-01-23 | Core Scientific | Sale to issuer (buyback) · Common Stock, par value $0.0001 per share | 1,518,472 | - | $20.12M |
| 2024-01-23 | Core Scientific | Grant / award / vesting · Common Stock, par value $0.00001 per share | 1,518,472 | - | $20.12M |
| 2022-08-15 | Core Scientific | Grant / award / vesting | 1,000,000 | - | $13.25M |
| 2022-06-13 | Core Scientific | Grant / award / vesting | 560,052 | - | $7.42M |
| 2022-06-13 | Core Scientific | Tax withholding on vesting | 41,580 | $83,992 | $550.9K |